Agenus (NASDAQ:AGEN) Trading Down 7.7%

Shares of Agenus Inc. (NASDAQ:AGEN – Get Rating) dropped 7.7% during trading on Friday . The stock traded as low as $1.69 and last traded at $1.69. Approximately 2,193,789 shares were traded during mid-day trading, a decline of 53% from the average daily volume of 4,654,724 shares. The stock had previously closed at $1.83.

Wall Street Analyst Weigh In

AGEN has been the topic of several recent analyst reports. StockNews.com initiated coverage on shares of Agenus in a research note on Thursday. They issued a “sell” rating on the stock. EF Hutton Acquisition Co. I reaffirmed a “buy” rating and issued a $8.30 price target on shares of Agenus in a research note on Wednesday. Finally, HC Wainwright reissued a “buy” rating and set a $8.00 target price on shares of Agenus in a research report on Tuesday, February 28th. One equities research analyst has rated the stock with a sell rating and three have issued a buy rating to the company’s stock. According to MarketBeat.com, Agenus has an average rating of “Moderate Buy” and a consensus target price of $7.10.

Agenus Trading Down 7.1 %

The business’s 50-day simple moving average is $2.27 and its 200 day simple moving average is $2.44.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. U.S. Capital Wealth Advisors LLC bought a new stake in shares of Agenus in the 1st quarter valued at about $25,000. Leisure Capital Management bought a new stake in shares of Agenus in the 3rd quarter valued at about $26,000. Commonwealth Equity Services LLC bought a new stake in shares of Agenus in the 3rd quarter valued at about $26,000. Calamos Advisors LLC bought a new stake in shares of Agenus in the 4th quarter valued at about $27,000. Finally, Jump Financial LLC bought a new stake in shares of Agenus in the 3rd quarter valued at about $29,000. Hedge funds and other institutional investors own 53.81% of the company’s stock.

About Agenus

(Get Rating)

Agenus, Inc is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H.